Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer (specifically a type called adenocarcinoma), confirmed through a tissue or cell sample test.
- People whose prostate cancer has spread to other parts of the body (metastatic), but only at a low level — meaning they do not have cancer spread to internal organs, and have fewer than four bone spots, or bone spots only within the spine or pelvis.
- People who have been diagnosed with prostate cancer that has spread but still responds to hormone-reducing treatment (sometimes called hormone-sensitive prostate cancer).
- People who have already been placed on a three-drug treatment plan by their doctor, regardless of whether they are enrolled in this study.
- People who started hormone-suppressing treatment (ADT) either within six months before the study reference date or at that date.
- People (or their legal representatives, if the patient has passed away) who have provided signed consent to participate — in some situations where signed consent is difficult to obtain, an opt-out consent process may be accepted in line with ethical guidelines.
Who may not be able to join:
- People who received the chemotherapy drug docetaxel before starting the drug darolutamide.
- People who are taking part in another research program that involves treatments outside of standard clinical care.
- People for whom darolutamide, docetaxel, or hormone-suppressing treatment (ADT) are not medically suitable, based on locally approved prescribing rules.
- People who are already participating in a specific related safety study of darolutamide for this type of prostate cancer (the DADOX study, trial number NCT06010914).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (+)1-888-84 22937
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with absolute prostate-specific antigen (PSA) response at 12 months; Number of patients with adverse event of special interests (AESIs), serious adverse events (SAEs) and adverse events (AEs) leading to dose modification or discontinuation of darolutamide or docetaxel at 12 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.